STAA Website: http://www.staar.com
The STAAR Visian ICL is a posterior chamber phakic intraocular lenses. Made of Collamer, STAAR’s proprietary collagen copolymer, the lens rests behind the iris in the ciliary sulcus. This unique material contains a small amount of collagen, which provides excellent biocompatibility and superior optical capability. The lens is gently folded and injected into the anterior chamber through a 3.0mm, temporal, clear corneal incision. The ICL is then carefully positioned by manipulating the footplates of the lens posterior to the iris plane and into the sulcus.
The ICL exhibits the following features:
Small Incision / Foldability – 3.0mm Incision
Posterior Chamber Implant – Invisible in the Eye
Sulcus Locating - Allows for a Toric Option
Made of Collamer – a proprietary biocompatible material
Experience - 5 Lens Designs and approximately 40,000 Implants
Wide Treatment Range
The ICL is made with Swiss precision from Collamer. Collamer, a collagen copolymer is a proprietary biocompatible material formed from pure collagen and a hydrophilic copolymer with a UV absorbent chromophore.
Q. Am I a candidate for the ICL?
A. The best candidates for the Visian ICL are between the ages of 21 and 45, with moderate to severe myopia.
It is best if the candidate has not had any previous ophthalmic surgery and does not have a history of ophthalmic disease such as glaucoma, iritis or diabetic retinopathy.
Q. What are the advantages of the ICL?
A. The Visian ICL is capable of correcting a wide range of myopia without the removal or destruction of corneal tissue. The ICL is a small, foldable, injectable lens that is inserted through a tiny, 3 mm incision that does not require sutures. The ICL provides predictable refractive outcomes and excellent quality of vision due to its placement inside the eye, as well as its optical performance. The lens is made of a superior lens material called Collamer, which provides unparalleled biocompatibility.
Q. What if a patient’s vision changes?
A. If there are major changes in ones vision the Visian ICL can easily be removed and replaced, or another procedure can be done at any time. With the ICL, one can still wear glasses or contact lenses if necessary. The ICL does not help presbyopia, or the need for reading glasses due to age. The ICL is available for different treatment ranges depending on what country you live in.
Q. Can they dry out or get dirty like a contact lens?
A. No. The Visian ICL is designed to remain in place within the eye without maintenance. An annual examination done by your ophthalmologist is recommended to make sure that everything is fine.
Q. Can the ICL be seen by the naked eye?
A. No. Because the lens is positioned behind the iris, neither you, nor an observer will be able to identify the lens in place. The cosmetic appearance of the Visian ICL is perfect, and there is no way for a non-professional to notice that a visual correction is in place.
Q. What are ICLs made of?
A. The material is called Collamer, a collagen co-polymer that contains a small amount of purified collagen. It is very biocompatible (doesn't cause a reaction inside the eye) and stable. It also contains an ultraviolet light filter. This material is proprietary to STAAR Surgical.
Q. What is involved in the ICL procedure?
A. The ICL surgery is performed on an outpatient basis, which means that the patient has surgery and leaves the same day. Please note that someone will have to drive the patient to and from surgery. A light, topical or local anesthetic is administered and there is very little discomfort and normally no pain associated with the procedure. Some drops or perhaps oral medication may be prescribed and a visit is usually scheduled the day after surgery.
Staar Surgical Myopia Treatment Approved
Friday December 23, 6:51 am ET
Staar Surgical Says FDA Approves Treatment to Correct Nearsightedness
MONROVIA, Calif. (AP) -- Staar Surgical Co., a developer of eye-care products, said Friday the Food and Drug Administration approved the company's Myopic Visian ICL for use in the correction of nearsightedness in adults.
The product, an implantable collamer lens, is the only minimally invasive foldable lens of its kind approved for the U.S. commercial market. As a result of the product's foldable design, the ICL procedure allows an incision up to 50 percent smaller than competing technology, Staar said.
The ICL is approved for sale in 41 countries, including the European Union, and has successfully been implanted in more than 40,000 eyes worldwide.
The company expects to begin shipping the Visian ICL in six to eight weeks. Doctors must be trained and certified to use the lens, and Staar said more than 860 surgeons have completed the first phase of training.
"The ICL remains our most significant opportunity for profitable growth going forward and receipt of FDA approval represents a critical milestone," said David Bailey, president and CEO of Staar Surgical.